Genetics of renal tumours

Cancer and Metastasis Reviews

Volumn 16, Issue 1-2, 1997, Pages 127-140

  Fleming, Stewart ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

carcinoma; Denys Drash syndrome; kidney; von Hippel Lindau; Wilms' tumour

Indexed keywords

HUMAN; KIDNEY CARCINOMA; MOLECULAR GENETICS; NEPHROBLASTOMA; PRIORITY JOURNAL; REVIEW;

BECKWITH-WIEDEMANN SYNDROME; CARCINOMA, RENAL CELL; CHROMOSOME MAPPING; DISEASE SUSCEPTIBILITY; DNA-BINDING PROTEINS; GENES, P53; GENES, TUMOR SUPPRESSOR; GENOMIC IMPRINTING; HIPPEL-LINDAU DISEASE; HUMANS; KIDNEY NEOPLASMS; LIGASES; PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; WILMS TUMOR; WT1 PROTEINS;

EID: 0030906349     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005700508194     Document Type: Review

References (144)

1. Fleming S: The impact of genetics on the classification of renal carcinoma. Histopathology 22: 89-92, 1993
2. Knudson AG, Strong LC: Mutation and cancer: a model for Wilms' tumour of the kidney. J Natl Cancer Inst 48: 313-324, 1972
3. Knudson AG: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-824, 1971
4. Francke V, Holmes LB, Atkins L, Riccardi VM: Aniridia-Wilms' tumour association: evidence for specific deletion of 11p13. Cytogenet Cell Genet 24: 185-192, 1979
5. Riccardi VM, Sujansky E, Smith AC: Chromosomal imbalance in the aniridia-Wilms' tumour association: 11p interstitial deletions. Paediatrics 61: 604-610, 1978
6. Huerre C, Despoisse S, Gilgenkrantz S, Lenoir GM. Junien C: c-Ha-ras 1 is not deleted in aniridia-Wilms' tumour association. Nature 305: 638-641, 1983
7. DeMartinville B, Francke U: The c-Ha-ras 1, insulin and globin loci map outside the deletion associated with aniridia-Wilms' tumour. Nature 305: 641-643, 1983
8. Glaser T, Lewis WH, Bruns GA et al.: The beta subunit of follicle stimulating hormone is deleted in patients with aniridia and Wilms' tumour, allowing a further definition of the WAGR locus. Nature 321: 882-885, 1986
9. Koufos A, Hansen MF, Lampkin BC et al.: Loss of alleles at loci on human chromosome 11 during genesis of Wilms' tumour. Nature 309: 170-172, 1984
10. Orkin SH, Goldman DS, Sallan SE: Development of homozygosity for chromosome 11p markers in Wilms' tumour. Nature 309: 172-174, 1984
11. Reeve AE, Housiax PJ, Gardner RJ, Chewings WE, Grindlay RM, Millow LJ: Loss of a Harvey ras allele in sporadic Wilms' tumour. Nature 309: 174-176, 1984
12. Fearon ER, Vogelstein B, Feinberg AP: Somatic deletion and duplication of genes on chromosome 11 in Wilms' tumours. Nature 318: 176-178, 1984
13. Davis LM, Stallard R, Thomas GH, Couillin P, Junien C, Nowak NH, Shows TB: Two anonymous DNA segments distinguish the Wilms' tumour and aniridia loci. Science 241: 840-842, 1988
14. Van Heyningen V, Bickmore WA, Seawright A et al.: Role for Wilms' tumour gene in genital development? Proc Natl Acad Sci 87: 5383-5386, 1990
15. Ton CCT, Hirvonen H, Miwa H et al.: Positional cloning and characterisation of a paired box - and homeobox - containing gene from the aniridia region. Cell 67: 1059-1074, 1991
16. Lewis WH, Yeger H, Bonetta L et al.: Homozygous deletion of a DNA marker from chromosome 11p13 in sporadic Wilms' tumor. Genomics 3: 25-31, 1988
17. Rose EA, Glaser T, Jones C et al.: Complete physical map of the WACiR region of 11p13 localizes a candidate Wilms' tumor gene. Cell 60: 495-508, 1990
18. Call KM, Glaser T, Ito Y et al.: Isolation and characterisation of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60: 509-520, 1990
19. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP: Homozygous deletion in Wilms' tumours of a zinc finger gene identified by chromosome jumping. Nature 343: 774-778, 1990
20. Pritchard-Jones K, Fleming S, Davidson D et al.: The candidate Wilms' tumour gene is involved in genitourinary development. Nature 346: 194-197, 1990
21. Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman D: Expression of the Wilms' tumour gene WT-1 in the murine urogenital system. Genes Development 5: 1345-1356, 1991
22. Kreidberg JA, Sariola H, Loring JM et al.: WT-1 is required for early kidney development. Cell 74: 679-691, 1993
23. Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterfacht A, Zabel B: Nuclear localisation of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adutl tissues. Development 119: 1329-1341, 1993
24. Pavletich NP, Pabo CO: Zinc finger DNA recognition: crystal structure of a Z if 268-DNA complex at 2,1 A. Science 252: 809-817, 1991
25. Madden SL, Cook DM, Rauscher III FJ: A structure function analysis of transcriptional repression mediated by the WT-1, Wilms' tumor suppressor protein. Oncogene 8: 1713-1720, 1993
26. Reddy JC, Morris JC, Wang J, English MA, Haber DA, Shi Y, Liet JD: WT1 mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem 270: 10878-10884, 1995
27. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman D: Alternative splicing and genomic structure of Wilms' tumor gene WT1. Proc Natl Acad Sci USA 86: 9618-9622, 1991
28. Sukhatme VP, Cao Zimin, Chang LC et al.: A zinc finger encoding gene coregulated with c-fos during growth and differentiation, and alter cellular depolarisation. Cell 53: 37-43, 1988
29. Christy B, Nathans D: DNA binding site of the growth factor inducible protein Zif 268. Proc Natl Acad Sci USA 86: 8737-8741, 1989
30. Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VP, Rauscher III FJ: Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science 253: 1550-1553, 1991
31. Wang Zhav Yi, Madden SL, Deuel TF, Rauscher III FJ: The Wilms' tumor gene product. WT1 represses transcription of the platelet derived growth factor A-chain gene. J Biol Chem 267: 21999-22002, 1992
32. Warner H, Re GG, Drummond IA et al.: Increased expression of the insulin like growth factor 1 receptor gene, IGFIR, in Wilms' tumor is correlated with modulation of IGFIR promoter activity by the WT1 Wilms' tumor gene product. Proc Natl Acad Sci USA 90: 5828-5832, 1993
33. Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, Douglass EC, Housman DR: An internal delection within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 61: 1257-1269, 1990
34. Cowell JK, Wadey RB, Haber DA, Call KM, Housmann D, Pritchard J: Structural rearrangements of the WT1 gene in Wilms' tumor cells. Oncogene 5: 595-599, 1991
35. Tadokoro K, Fujii H, Ohshima A et al.: Intragenic homozygous deletion of the WT1 gene in Wilms' tumor. Oncogene 7: 1215-1221, 1992
36. Coppes MJ, Liefers GJ, Paul P, Yeger H, Williams BRG: Homozygous somatic WT1 point mutations in sporadic unilateral Wilms' tumor. Proc Natl Acad Sci USA 90: 1316-1419, 1993
37. Haber DA, Buckler AJ, Glaser T et al.: An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumour. Cell 61: 1257-1269, 1990
38. Denys P, Hahraux P, Van den Berghe H, Tanghe W, Proesmans W: Association d'un syndrome anatomo-pathologique de pseudohermaphroditism masculin, d'une tumeur de Wilms, d'une nephropathie parenchymateuse et d'un mosaicisme XX/XY. Arch Fran Ped 24: 729-739, 1967
39. Drash A, Sherman F, Hartmann WH, Blizzard RM: A syndrome of pseudohermaphroditism, Wilms' tumour, hypertension and degenerative renal disease. J Pediat 76: 585-593, 1970
40. Mueller RF: The Denys-Drash syndrome. J Med Genet 31: 471-477, 1994
41. Frasier SD, Bashore RA, Mosier HD: Gonadoblastoma associated with pure gonadal dysgenesis in monozygous twins. J Paediat 64: 740-745, 1964
42. Moorthy AV, Chesney RW, Lubinsky M: Chronic renal failure and XY gonodal dysgenesis: Frasier's syndrome - a commentary on reported cases. Am J Med Genet (Suppl) 3: 297-302, 1987
43. Pelletier J, Breuning W, Kashtan CE et al.: Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys Drash Syndrome. Cell 67: 437-447, 1991
44. Breuning W, Bardeesy N, Silverman BL et al.: Germline intronic and exonic mutations in the Wilms' tumor gene (WT1) affecting urogenital development. Nature Genet 1: 144-148, 1992
45. Baird PN, Santos A, Groves N, Jacbesic L, Cowell JK: Constitutional mutations in the WT1 gene in patients with Denys Drash syndrome. Hum Mol Genet 1: 301-305, 1992
46. Little MH, Williamson KA, Manners M et al.: Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant negative fashion. Hum Mol Genet 2: 259-264, 1993
47. Nordenskjold A, Friçke G, Anvert M: Absence of mutations in the WT1 gene with XY gonadal dysgenesis. Human Genet 96: 102-104, 1995
48. Bardeesy N, Falkoff D, Petruzzi M, Nowak N, Zabel B, Adam M, Aguiar M, Grundy P, Pelletier J: Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nature Genet 7: 91-97, 1984
49. Little MH, Holmes G, Bickmore W, Van Heyningen V, Hastie N, Wainwright B: DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Human Molec Genet 4: 351-358, 1995
50. Larsson S, Charlieu J-P, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, Hastie N; Subnuclear localisation of WT1 in splicing or transaction factor domains is regulated by alternative splicing. Cell 81: 391-401, 1995
51. Pritchard-Jones K, Fleming S: Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumour: implications for tumour histogenesis. Oncogene 6: 2211-2220, 1991
52. Ramani P, Cowell J: The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours. J Pathol 179: 162-168, 1996
53. Huff V, Jaffe N, Saunders G, Strong L, Villalba F, Ruteshauser E: WT1 exon 1 deletion/insertion mutations in Wilms' tumour patients associated with di- and tri-nucleotide repeats and deletion hotspot consensus sequences. Am J Hum Genet 56: 84-90, 1995
54. Schneider S, Wildhardt G, Ludwig R, Roger-Pokara B: Exon slipping due to a mutation in a donor splice site in the WT-1 gene is associated with Wilms' tumor and severe genital malformations. Hum Genet 91: 599-604, 1993
55. Gessler M, Konig A, Arden K, Grady P, Orkin S, Sallan S, Peters C, Rugle S, Mandell J, Li F: Infrequent mutation of the WT1 gene in 77 Wilms' tumours. Hum Mutat 3: 212-222, 1994
56. Park S, Schalling M, Bernard A et al.: The Wilms' tumour gene WT1 is expressed in murine mesoderm derived tissues and mutated in a human mesothelioma. Nat Genet 4: 415-420, 1993
57. Ladanji M, Gerald W: Fusion of the EWS and WT1 genes in desmoplastic small round cell tumour. Cancer Res 54: 2837-2840, 1994
58. Pritchard-Jones K, Renshaw J, King-Underwood L: The Wilms' tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient. Hum Mol Genet 3: 1633-1637, 1994
59. King-Underwood L, Renshaw J, Pritchard-Jones K: Mutations in the Wilms' tumour gene WT1 in leukaemias. Blood 87: 2171-2179, 1996
60. Mannens M, Slater RM, Heyting C et al.: Molecular nature of genetic changes resulting in loss of helerozygosity of chromosome 11 in Wilms' tumour. Hum Genet 81: 41-48, 1988
61. Reeve AE, Sik SA, Raizis AM, Fernberg AP: Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumour cells. Mol Cell Biol 9: 1799-1803, 1989
62. Henry I, Bonnaittie-Pellie C, Chehemsse V: Uniparental paternal disomy in a genetic cancer predisposing syndrome. Nature 351: 665-667, 1991
63. Koufos A, Grundy P, Morgan K et al.: Familial Wiedemann-Beck with syndrome and a second Wilms' tumour locus both map to 11p15.5. Am J Hum Genet 44:711-719, 1989
64. Wadey RB, Pal N, Buckle B et al.: Loss of heterozygosity in Wilms' tumour involves two distinct regions of chromosome 11. Oncogene 5: 901-907, 1990
65. Beckwith JP: Extreme cytomegaly of the adrenal fetal cortex, omphalocele, hyperplasia of the kidneys and pancreas, and Leydig cell hyperplasia - another syndrome. Wester Society for Pediatric Researh, Los Angeles, California, 1963
66. Wiedemann HR: Complexe mulformatif familial avec hernie ombilicale et macroglossie - un 'syndrome nouveau'. J Genet Hum 13: 232-233, 1964
67. Ping AJ, Reeve AE, Law DJ et al.: Genetic linkage of Beckwith-Wiedemann Syndrome to 11p15. Am J Hum Genet 44: 720-723, 1989
68. Ohlsson R, Nystrom A, Pfeiffer-Ohlsson S et al.: IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nature Genet 4: 94-97, 1993
69. Giannoukakis N, Deal C, Paquette J et al.: Parental genomic imprinting of the human IGF2 gene. Nature Genet 44: 98-101, 1993
70. Barlow DP, Stoger R, Herrmann BG et al.: The mouse insulin-like growth factor type 2 receptor is imprinted and closely linked to the T one locus. Nature 349: 84-87, 1991
71. Zhang Y, Tycko B: Monoallelic expression of the human H19 gene. Nature Genet 1: 40-44, 1992
72. Rachmilewitz J, Gileadi O, Eldar-Gera T et al.: Transcription of the H19 gene in differentiating cytotrophoblasts from human placenta. Mol Reprod Dev 32: 196-202, 1992
73. Henry I, Bonaitie-Pellie C, Chehemsse V et al.: Uniparental paternal disomy in a genetic cancer predisposing syndrome Nature 351: 665-667, 1991
74. Morison IM, Becroft DM, Taniguchi T, Woods CG, Reeve AE: Somatic overgrowth associated with overexpression of insulin like growth factor II. Nature Med 2:311-316, 1996
75. Rogers SA, Ryan G, Hammerman MR: Insulin like growth factor I and II are produced in the metanaphros and are required for growth and development in vitro. J Cell Biol 113: 1447-1453, 1991
76. Reeve AE, Eccles MR, Wilkins RJ, Bell GI, Mellow LJ: Expression of insulin-like growth factor H transcripts in Wilms' tumour. Nature 317: 258-260, 1985
77. Scott J, Cowell JK, Robertson ME et al.: Insulin like growth factor II gene expression in Wilms' tumour and embryonic tissues. Nature 317: 260-262, 1985
78. Ogawa O, Eccles MR, Szeto J et al.: Relaxation of insulin like growth factor II gene imprinting in Wilms' tumour. Nature 362: 749-751, 1993
79. Weksberg R, Ding Ren Shen, Yan Ling Fei et al.: Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nature Genet 5: 143-150, 1993
80. Rainer S, Johnson LA, Dobry CJ et al.: Relaxation of imprinted genes in human cancer. Nature 362: 747-749, 1993
81. Little MH, Dunn R, Byrne JA et al.: Equivalent expression of paternally and maternally inherited WT1 alleles in normal fetal tissue and Wilms' tumours. Oncogene 7: 635-641, 1992
82. Brannan CI, Dees EC, Ingram RS, Tilghman SM: The product of the H19 gene may function as an RNA. Mol Cell Biol 10: 28-36, 1990
83. Lustig O, Ariel I, Ilan J et al.: Expression of the imprinted gene H19 in the human fetus. Mol Reprod Dev 38: 239-246, 1994
84. Goshen R, Rachmilewitz J, Schneider T et al.: The expression of the H19 and IGF2 genes during human embryogenesis and placental development. Mol Reprod Dev 34: 374-379, 1993
85. Ohlsson R, Hedborg F, Holmgren L et al.: Overlapping patterns of IGF2 and H19 expression during human development: biallelic IGF2 expression correlates with a lack of H19 expression. Development 120: 361-368, 1994
86. Hao Y, Crenshaw T, Muulton T et al.: Tumour-suppressor activity of H19 RNA. Nature 365: 764-767, 1993
87. Garvin AJ, Re GG, Tarnowski BI et al.: The G4O1 cell line, utilised for studies of chromosomal changes in Wilms' tumour is derived from a rhabdoid tumour of the kidney. Am J Path 142: 375-380, 1992
88. Moulton T, Crenshaw T, Hao Y et al.: Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nature Genet 7: 440-447, 1994
89. Steenman MJC, Rainer S, Dobry CJ et al.: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nature Genet 7: 433-439, 1994
90. Grundy P, Koufos A, Morgan K et al.: Familial predisposition to Wilms' tumour does not map to the short arm of chromosome 11. Nature 336: 374-376, 1988
91. Huff V, Compton DA, Chao LY et al.: Lack of linkage of familial Wilms' tumour to chromosome band 11p13. Nature 336: 377-378, 1988
92. Schwartz CE, Haber DA, Stanton VP et al.: Familial predisposition to Wilms' tumour does not segregate with the WT1 gene. Genomics 10: 927-930, 1991
93. Maw MA, Grundy P, Millow LJ et al.: A third Wilms' tumour locus on chromosome 16q. Cancer Res 52: 3094-3098, 1992
94. Huff V, Reeve AE, Leppert M et al.: Non linkage of 16q markers to familial predisposition to Wilms' tumour. Cancer Res 52: 6117-6120, 1992
95. Grundy P, Telzerow PE, Breslow N et al.: Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumours predicts an adverse outcome. Cancer Res 54: 2331-2333, 1994
96. Rahman N, Arbour L, Tonin P, Renshaw J, Pelletier J, Baruchal S, Pritchard-Jones P, Stratton MR, Narod SA: Evidence for familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. Nature Genet 13: 461-463, 1996
97. Narod S: Genetics of breast and ovarian cancer. Br Med Bull 50: 656-676, 1994
98. Stay EJ, Vawter G: The relationship between nephroblastoma and neuroblastoma. Cancer 39: 2550-2555, 1977
99. Szabo J: Hereditary hyperparathyroidism - jaw tumour syndrome: the endocrine tumour gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 56: 944-950, 1995
100. Pilia G et al.: Mutations in GPC3 aglypican gene cause the Simpson-Golabi-Behmel overgrowth syndrome. Nature Genet 12: 241-247, 1996
101. Cairney A, Andrews M, Greenberg M, Smith D, Weksberg R: Wilms' tumour in three patients with Bloom syndrome. J Paediat 111: 414-416, 1990
102. Neri G, Martin-Neri ME, Katz B, Opitz JM: The Perlman syndrome: familial renal dysplasia with Wilms' tumour, fetal gigantism and multiple congenital anomalies. Am J Med Genet 19: 195-207, 1984
103. Hartley AL et al.: Wilms' tumour in the Li-Fraumai cancer family syndrome. Cancer Genet Cytogenet 67: 133-135, 1993
104. Geiser C, Schindler A: Long term survival in a male with 18-trisomy syndrome and Wilms' tumour. Paediat 44: 111-116, 1960
105. Beckwith JB, Kiviat NB, Bonadio JF: Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumour. Pediat Pathol 10: 1-36, 1990
106. Park S, Bernard A, Bove KE et al.: Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. Nature Genet 5: 363-367, 1993
107. Erlandsson R, Boldog F, Sumegi J, Klein G: Do human renal cell carcinomas arise by a double loss mechanism? Cancer Genet Cytogenet 36: 197-203, 1988
108. Cohen AJ, Li FP, Berg S et al.: Hereditary renal carcinoma associated with a chromosomal translocation. N Engl J Med 301: 592-595, 1979
109. Kovacs S, Brusa P, De Rieses W: Tissue specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal cell carcinomas. Int J Cancer 43: 422-426, 1989
110. Kovacs G, Hoene E: Loss of der (3) in renal cell carcinoma cells of a patient with constitutional t (3;12). Human Genet 78: 148, 1988
111. Teyssier JR, Henry L Dozier C et al.: Recurrent deletion of the short arm of chromosome 3 in human renal carcinomas: shift of the c-raf locus. J Natl Cancer Inst 77: 1187-1192, 1986
112. Naylor SL, Marshall A, Hensel C et al.: The DNF 1552 locus at 3p21 is transcribed in normal lung at small cell lung cancer. Genomics 4: 335-339, 1989
113. Erlandsson R, Bergekeim USR, Boldog F et al.: A gene near the D3F15S2 site on 3p is expressed in normal human kidney but not or only at a severely reduced level in 11 of 15 primary renal cell carcinomas (RCC). Oncogene 5: 1207-1212, 1990
114. Maher ER, Yates JR, Harries R et al.: Clinical features and natural history of von Hippel Lindau disease. Q J Medicine 77: 1151-1163, 1990
115. Solomon W, Schwartz A: Renal pathology in von Hippel Lindau disease. Human Pathology 19: 1072-1079, 1988
116. Seizinger BR, Rouleau GA, Ozelius LJ et al.: Von Hippel Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332: 268-269, 1988
117. Yao M, Latif F, Orcutt ML, Kuzman I, Stackhouse T, Zhou FW, Tony K, Duk FM, Richards F, Maher E, Zbar B: Von Hippel Lindau disease: identification of deletion mutations by pulsed field gel electrophoresis. Hum Genet 92: 605-614, 1993
118. Latif F, Tory K, Gnarra J et al.: Identification of the Von Hippel-Lindau disease tumour suppressor gene. Science 260: 1317-1320, 1993
119. Richards FM, Schofield PN, Fleming S, Maher ER: Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 5: 639-644, 1996
120. Duan DR, Pause A, Burgess WH, Aso T, Chen DYT, Garrett C, Conaway RC, Conaway JW, Linehan WM, Klausner RD: Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269: 1402-1406, 1995
121. Aso T, Lane WS, Conaway JW, Conaway RC: Elongin (SI-II), a multisubunit regulator of elongation by RNA polymerase II. Science 269: 1439-1443, 1995
122. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG: Binding of the von Hippel Lindau tumor suppressor protein to elongin B and C. Science 269: 1444-1446, 1995
123. Zbar B, Brausen H, Talmadge C, Linehan M: Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327: 721-724, 1987
124. Kovacs G, Erlandssen R, Boldog F et al.: Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA 85: 1571-1575, 1988
125. Morita M, Ishikawa J, Tsutsumi M et al.: Allelotype of renal cell carcinoma. Cancer Res 51: 820-823, 1991
126. Foster K, Crossey PA, Cairns P, Hetherington JW, Richards FM, Jones MH, Bentley E, Affara NA, Ferguson-Smith MA, Maher ER: Molecular genetic investigations of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22. Br J Cancer 69: 230-234, 1994
127. Gnarra JR, Tory K, Weng Y et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet 7: 85-90, 1994
128. Shuin T, Kondo K, Torigo S et al.: Frequent somatic mutations and loss of heterozygosity of the Von Hippel Lindau tumour suppressor gene in primary human renal cell carcinomas. Cancer Res (in press), 1994
129. Foster K, Prowse A, Van den Berg A et al.: Somatic mutations of the Von Hippel Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma (in press), 1994
130. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samíd D, Duan DR, Gnarra JR, Linehan WM, Baylin SB: Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700-9704, 1996
131. Ishikawa I, Kovacs G: High incidence of papillary renal cell tumours in patients on chronic haemadialysis. Histopathology 22: 135-139, 1993
132. Kovacs G: Molecular differential pathology of renal cell tumours. Histopathology 22: 1-8, 1993
133. Kovacs A, Kovacs G: Low chromosome number in chromophobe renal cell carcinomas. Genes Chromosome Cancer 4: 267-268, 1992
134. Kovacs A, Storkel S, Thoenes W, Kovacs G: Mitrochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas. J Pathol 167: 273-277, 1992
135. Kovacs G, Weiler C, Wilkens L et al.: Renal oncocytoma - a phenotypic and genetic entity of renal parenchymal tumours. Am J Pathol 134: 967-971, 1989
136. Fuzesi L, Cober M, Mittermayer CR: Collecting duct carcinoma: cytogenetic characterisation. Histopathology 21: 155-160, 1992
137. Weber PG, Chen J, Nisen PD: Infrequency of ras, p53, WT1 or RB gene alterations in Wilms' tumours. Cancer 72: 3732-3738, 1993
138. Bardeesy N, Falkoff D, Petruzzi M-J et al.: Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nature Genetics 7: 91-97, 1994
139. Lemoine NR, Hughes CM, Cowell JK: Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumours. J Pathol 168: 237-242, 1992
140. Zuppan CW, Beckwith JB, Luckey PW: Anaplasia in unilateral Wilms' tumour: a report from the national Wilms' tumour study center. Hum Pathol 19: 1199-1209, 1988
141. Bardeesy N, Beckwith JB, Pelletier J: Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res 55: 215-219, 1996
142. Uchida T, Wada C, Shitara T, Egawa S, Mashimo S, Koshiba K: Infrequent involvement of p53 mutations and loss of heterozygosity of 17p in the lumourigenesis of renal cell carcinoma. J Urol 150: 1298-1301, 1993
143. Uchida T, Wada C, Wang C, Egawa S, Ohtani H, Koshiba K: Genomic instability of microstaellite repeals and mutations of K-, H- and N-ras and p53 genes in renal cell carcinoma. Cancer Res 54: 3682-3685, 1994
144. Kunimi K, Uchibayashi T, Hisazumi H: Oncogene amplification and inactivation of tumour genes in urological malignant tumours. Jap J Urol 82: 1930-1936, 1991